Cargando…
Dapagliflozin: a sodium glucose cotransporter 2 inhibitor in development for type 2 diabetes
Type 2 diabetes mellitus (T2DM) is a growing worldwide epidemic. Patients face lifelong therapy to control hyperglycemia and prevent the associated complications. There are many medications, with varying mechanisms, available for the treatment of T2DM, but almost all target the declining insulin sen...
Autores principales: | Tahrani, Abd A., Barnett, Anthony H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare Communications
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3138480/ https://www.ncbi.nlm.nih.gov/pubmed/22127745 http://dx.doi.org/10.1007/s13300-010-0007-3 |
Ejemplares similares
-
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
por: List, James F., et al.
Publicado: (2009) -
Sodium–glucose cotransporter 2 inhibitor Dapagliflozin attenuates diabetic cardiomyopathy
por: Arow, M., et al.
Publicado: (2020) -
Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus
por: Fioretto, Paola, et al.
Publicado: (2015) -
Effect of the Sodium-Glucose Cotransporter 2 Inhibitor, Dapagliflozin, on Genitourinary Infection in an Animal Model of Type 2 Diabetes
por: Choi, Jin Bong, et al.
Publicado: (2020) -
Therapeutic effects on the development of heart failure with preserved ejection fraction by the sodium-glucose cotransporter 2 inhibitor dapagliflozin in type 2 diabetes
por: Feng, Bin, et al.
Publicado: (2023)